Publication:
Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets

Simple item page
dc.contributor.authorBedoya, Luis M
dc.contributor.authorBeltran, Manuela
dc.contributor.authorGarcía-Pérez, Javier
dc.contributor.authorObregon-Calderon, Patricia
dc.contributor.authorCallies, Oliver
dc.contributor.authorJímenez, Ignacio A
dc.contributor.authorBazzocchi, Isabel L
dc.contributor.authorAlcamí, José
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderComplutense University of Madrid (España)
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.date.accessioned2020-03-04T12:03:06Z
dc.date.available2020-03-04T12:03:06Z
dc.date.issued2018
dc.description.abstractCurrent research on antiretroviral therapy is mainly focused in the development of new formulations or combinations of drugs belonging to already known targets. However, HIV-1 infection is not cured by current therapy and thus, new approaches are needed. Bevirimat was developed by chemical modification of betulinic acid, a lupane-type pentacyclic triterpenoid (LPT), as a first-in-class HIV-1 maturation inhibitor. However, in clinical trials, bevirimat showed less activity than expected because of the presence of a natural mutation in Gag protein that conferred resistance to a high proportion of HIV-1 strains. In this work, three HIV-1 inhibitors selected from a set of previously screened LPTs were investigated for their targets in the HIV-1 replication cycle, including their maturation inhibitor effect. LPTs were found to inhibit HIV-1 infection acting as promiscuous compounds with several targets in the HIV-1 replication cycle. LPT12 inhibited HIV-1 infection mainly through reverse transcription, integration, viral transcription, viral proteins (Gag) production and maturation inhibition. LPT38 did it through integration, viral transcription or Gag production inhibition and finally, LPT42 inhibited reverse transcription, viral transcription or Gag production. The three LPTs inhibited HIV-1 infection of human primary lymphocytes and infections with protease inhibitors and bevirimat resistant HIV-1 variants with similar values of IC50. Therefore, we show that the LPTs tested inhibited HIV-1 infection through acting on different targets depending on their chemical structure and the activities of the different LPTs vary with slight structural alterations. For example, of the three LPTs under study, we found that only LPT12 inhibited infectivity of newly-formed viral particles, suggesting a direct action on the maturation process. Thus, the multi-target behavior gives a potential advantage to these compounds since HIV-1 resistance can be overcome by modulating more than one target.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThis work was supported by the Universidad Complutense de Madrid (UCM-Santander PR26/16-20281), the Instituto de Salud Carlos III (ISCIII-FIS PI16CIII/00034) and the Spanish AIDS Research Network RD12/0017/0015 that is included in the Spanish I+D+I Plan and is co-financed by ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development (FEDER) and by the SAF2015-65113-C2-1-R MINECO Spain project and FEDER funds from the EU. We also thank to Centro de Transfusión de la Comunidad de Madrid for the supply of Buffy-coatses_ES
dc.format.page358es_ES
dc.format.volume9es_ES
dc.identifier.citationFront Pharmacol. 2018 Apr 18;9:358.es_ES
dc.identifier.doi10.3389/fphar.2018.00358es_ES
dc.identifier.issn1663-9812es_ES
dc.identifier.journalFrontiers in pharmacologyes_ES
dc.identifier.pubmedID29720939es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9176
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/UCM-Santander PR26/16-20281es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/ISCIII-FIS PI16CIII/00034es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/ RD12/0017/0015es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-65113-C2-1-Res_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fphar.2018.00358es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIV-1es_ES
dc.subjectAntiretroviralses_ES
dc.subjectLupaneses_ES
dc.subjectMaturationes_ES
dc.subjectMulti-target compoundses_ES
dc.subjectPromiscuous compoundses_ES
dc.subjectTriterpenoidses_ES
dc.titlePromiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targetses_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication51e14860-d081-4f16-8e7c-8ed3c8c26722
relation.isAuthorOfPublication0afbdacd-48b9-407c-a9b6-3acdfccf86ec
relation.isAuthorOfPublicationdfc1fc6c-bf29-47c1-b48d-73f13c6c0865
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery51e14860-d081-4f16-8e7c-8ed3c8c26722
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PromiscuousMultiTargetLupane_2018.pdf
Size:
1.62 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Centro Nacional de Microbiología (CNM)